News and updates

Agendia and Angsana to Provide Breast Cancer Risk-of-Recurrence Testing with MammaPrint and BluePrint to Patients in Southeast Asia

May 24, 2018

Partnership will enable women in Singapore, Malaysia, Vietnam, Brunei and Myanmar to access the benefits of MammaPrint® and BluePrint® to personalize treatment management decisions for early breast cancer IRVINE, CA AND AMSTERDAM, NETHERLANDS – 24 May 2018 – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, and Angsana Molecular & Diagnostics…

Read more

Agendia’s MammaPrint and BluePrint Breast Cancer Tests Selected by Unicancer for French Patients

May 15, 2018

IRVINE, CA, AMSTERDAM, NETHERLANDS – 15 May 2018 – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announce that Unicancer, a hospital group entirely devoted to fighting cancer, has selected the MammaPrint® Breast Cancer Risk of Recurrence test and BluePrint® Molecular Subtyping test for use in its 18 French Comprehensive Cancer…

Read more

Agendia’s MammaPrint Receives Positive Coverage Decisions from Three Major Private Healthcare Insurers

May 1, 2018

Decisions from Aetna, Cigna and UnitedHealthcare followed the latest update to the American Society of Clinical Oncology (ASCO) guidelines recommending MammaPrint® Breast Cancer Risk of Recurrence Test for certain breast cancer patients Majority of U.S. breast cancer patients will now be covered for MammaPrint, which could result in significant cost savings IRVINE, CA AND AMSTERDAM,…

Read more

Agendia Announces CE Mark for NGS-Based MammaPrint BluePrint Kit Enhancing Access to Personalized Treatment for Breast Cancer Patients in Europe

March 21, 2018

IRVINE, CA, AMSTERDAM, NETHERLANDS – 21 March 2018 – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, today announces that its next-generation sequencing (NGS)-based MammaPrint® BluePrint® Breast Cancer Recurrence and Molecular Subtyping Kit is now CE marked, enabling the Company to commercialize the device in Europe. Dr. Marjolaine Baldo, Commercial Vice…

Read more